Verenigde Staten - Engels - NLM (National Library of Medicine)

mayne pharma - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) - tazarotene 1 mg in 1 g - fabior® (tazarotene) foam, 0.1% is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. fabior foam is contraindicated in pregnancy. fabior foam may cause fetal harm when administered to a pregnant woman. tazarotene elicits teratogenic and developmental effects associated with retinoids after topical or systemic administration in rats and rabbits [see use in specific populations (8.1)]. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus  [see warnings and precautions (5.1), use in specific populations (8.1)]. fabior foam is contraindicated in pregnancy  [see contraindications (4)]. there are no adequate and well-controlled studies with fabior foam in pregnant women. fabior foam is contraindicated in females who are or may become pregnant [see contraindications (4)]. females of child-bearing potential should be warned of the poten

Verenigde Staten - Engels - NLM (National Library of Medicine)

stiefel laboratories, inc. - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) - tazarotene 1 mg in 1 g

Australië - Engels - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - tazarotene -

Verenigde Staten - Engels - NLM (National Library of Medicine)

almirall, llc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) - tazorac® (tazarotene) gel, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. tazorac (tazarotene) gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. the efficacy of tazorac gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. the safety of tazorac gel use on more than 20% body surface area has not been established in psoriasis or acne [see warnings and precautions ( 5.1 ) and use in specific populations ( 8.1 )]. tazorac gel is contraindicated in:  - pregnancy. retinoids may cause fetal harm when administered to a pregnant female [see warnings and precautions ( 5.1 ), use in specific populations ( 8.1 , 8.3 )]. - individuals who have known hypersensitivity to any of its components [see warnings and precautions ( 5.2 )]. risk summary based on data from animal reproduction studies, ret

Verenigde Staten - Engels - NLM (National Library of Medicine)

bausch health us, llc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) - arazlo ® (tazarotene) lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. arazlo is contraindicated in pregnancy. arazlo may cause fetal harm when administered to a pregnant patient [see warnings and precautions (5.1), use in specific populations (8.1, 8.3)] . risk summary arazlo is contraindicated in pregnancy. there are no available data on arazlo use in pregnant patients to inform a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, arazlo may cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. the potential risk to the fetus outweighs the potential benefit to the mother; therefore, arazlo should be discontinued as soon as pregnancy is recognized. in animal reproduction studies with pregnant rats, reduced fetal body weights

Canada - Engels - Health Canada

ipsen biopharmaceuticals canada inc - palovarotene - capsule - 1mg - palovarotene 1mg

Canada - Engels - Health Canada

ipsen biopharmaceuticals canada inc - palovarotene - capsule - 1.5mg - palovarotene 1.5mg

Canada - Engels - Health Canada

ipsen biopharmaceuticals canada inc - palovarotene - capsule - 2.5mg - palovarotene 2.5mg

Canada - Engels - Health Canada

ipsen biopharmaceuticals canada inc - palovarotene - capsule - 5mg - palovarotene 5mg

Canada - Engels - Health Canada

ipsen biopharmaceuticals canada inc - palovarotene - capsule - 10mg - palovarotene 10mg